FDA approves Rinvoq for treatment of atopic dermatitis
The U.S. Food and Drug Administration approved Rinvoq (upadacitinib) for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older, the manufacturer announced Friday.
Jan 19, 2022
0
4